Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOCHOLEST LIGHT vs AMINOSYN 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Adjunctive therapy to diet for reduction of elevated LDL cholesterol in primary hypercholesterolemia (Fredrickson Type IIa) in patients who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: adjunct in treatment of hyperthyroidism (binding of thyroxine), pseudomembranous colitis (binding of Clostridioides difficile toxins), and digoxin toxicity
Parenteral nutrition for patients with inadequate oral or enteral intake,Prevention of nitrogen loss in catabolic states,Treatment of negative nitrogen balance
LOCHOLEST LIGHT is not a recognized drug name. No data available.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Not metabolized; excreted unchanged in feces as the bile acid-resin complex.
Amino acids are metabolized primarily in the liver via deamination, transamination, and other pathways. The carbon skeletons enter the citric acid cycle or gluconeogenesis, and nitrogen is converted to urea.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Amino acids: negligible protein binding (<5%); albumin binds some tryptophan and branched-chain amino acids minimally.
Apparent volume of distribution is approximately 0.5-0.7 L/kg; extensive distribution into extravascular tissues, including the liver, which is the primary site of action.
Amino acids: 0.3-0.5 L/kg (approximates extracellular fluid volume); clinical meaning: distributes primarily in ECF.
Oral bioavailability is low (approximately 5-10%) due to extensive first-pass metabolism in the liver and gut wall; food increases absorption slightly (no dosage adjustment required).
Intravenous: 100% (only route of administration); not absorbed orally as parenteral formulation.
No data available.
GFR <50 m L/min: reduce dose to 0.5-0.8 g/kg/day. GFR <15 m L/min: avoid or use with extreme caution, monitor serum amino acids.
No data available.
Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated due to risk of hepatic encephalopathy.
No data available.
Neonates: 2-3 g/kg/day IV. Infants/children: 1.5-2.5 g/kg/day IV. Adjust based on metabolic status and growth.
No data available.
Initiate at low end of adult dose (1 g/kg/day IV), monitor renal function and adjust accordingly; consider reduced metabolic clearance.
No FDA boxed warning.
None
May cause hypertriglyceridemia; monitor triglycerides. Risk of bleeding due to vitamin K deficiency with long-term use. May reduce absorption of fat-soluble vitamins (A, D, E, K). Can cause fecal impaction; use with caution in constipation-prone patients. May bind other drugs; separate administration by at least 4 hours.
Risk of hyperammonemia, especially in patients with hepatic impairment or inborn errors of urea cycle,Electrolyte imbalances may occur; monitor serum electrolytes frequently,Monitor for signs of infection at infusion site,Use caution in patients with renal impairment, as accumulation of amino acids may occur,May cause metabolic acidosis in certain patients
Complete biliary obstruction (ineffective and may cause fecal impaction), hypersensitivity to any component, severe constipation or fecal impaction, hypolipidemic states (e.g., abetalipoproteinemia).
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria),Severe hepatic failure with hyperammonemia,Severe renal failure without dialysis support,Patients with uncorrected electrolyte imbalances
Cholestyramine binds to bile acids and can interfere with absorption of fat-soluble vitamins (A, D, E, K). Patients should consume a diet rich in these vitamins or consider supplementation. High-fiber foods may aid in reducing constipation. Avoid excessive intake of high-fat foods as they may worsen hypertriglyceridemia.
No direct food interactions, but ensure adequate non-protein calorie intake (carbohydrates, fats) to prevent amino acid utilization for energy. Avoid concurrent use with high-protein oral diets without medical supervision. For patients with phenylketonuria (PKU), verify product composition as some contain phenylalanine.
First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documented human fetal adverse effects. Overall, use only if clearly needed.
Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. In the first trimester, the risk of teratogenicity is theoretical; essential amino acids are necessary for fetal development, but excesses or imbalances may be harmful. During the second and third trimesters, supplementation may be beneficial for maternal and fetal nutrition, but potential risks include metabolic acidosis or electrolyte disturbances if not properly monitored.
Excretion in human milk unknown. Caution advised. M/P ratio not available.
Aminosyn 10% is not excreted into breast milk in significant amounts; its components are endogenous substances. The M/P ratio is not applicable as it is not a drug with active transport. Maternal use during breastfeeding is considered safe if the infusion is necessary for maternal health. No adverse effects on the nursing infant are expected.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnancy.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering amino acid clearance. However, no specific dose adjustments are established for Aminosyn 10%. Dosage should be individualized based on nitrogen balance, weight gain, and metabolic parameters. Close monitoring of amino acid levels and metabolic status is recommended to avoid toxicities or deficiencies.
Locholest Light (cholestyramine) is a bile acid sequestrant used for hyperlipidemia. Monitor for decreased absorption of fat-soluble vitamins (A, D, E, K) and consider supplementation. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. May increase triglyceride levels; avoid in patients with hypertriglyceridemia above 400 mg/d L. Can cause constipation; ensure adequate fluid and fiber intake.
Use central line administration for concentrations >5% to reduce thrombophlebitis risk. Monitor serum electrolytes, BUN, glucose, and liver function tests frequently. Adjust infusion rate based on metabolic tolerance; start at 100 m L/hr and increase gradually. Contraindicated in severe hepatic disease, uremia, or maple syrup urine disease. Do not use as a sole source of nutrition; provide concurrent calories from carbohydrates and fats.
Take cholestyramine exactly as prescribed, usually mixed with at least 4-6 ounces of fluid.,Do not take the powder dry; always mix with water, juice, or milk to avoid choking.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Report unusual bleeding, bruising, or dark stools as signs of vitamin K deficiency.,This medication may increase triglyceride levels; monitor blood tests as directed.
This solution provides amino acids for protein building when you cannot eat normally.,Report signs of infection at catheter site: redness, swelling, pain, or drainage.,Common side effects include nausea, flushing, and warmth during infusion.,You will need regular blood tests to monitor kidney, liver, and metabolic function.,Inform your doctor if you have diabetes, kidney disease, or a history of gout.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOCHOLEST LIGHT vs AMINOSYN 10%, answered by our medical review team.
LOCHOLEST LIGHT is a Bile Acid Sequestrant that works by Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.. AMINOSYN 10% is a Parenteral Nutrition Solution that works by Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOCHOLEST LIGHT and AMINOSYN 10% depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOCHOLEST LIGHT is: LOCHOLEST LIGHT is not a recognized drug name. No data available.. The standard adult dose of AMINOSYN 10% is: Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOCHOLEST LIGHT and AMINOSYN 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOCHOLEST LIGHT is classified as Category C. First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documente. AMINOSYN 10% is classified as Category C. Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.